



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Ziilli et al.

Application No. 10/080,942

Filed: February 22, 2002

Title: COSMETICS CONTAINING  
ISOFLAVONE AGLYCONES

)  
) Attorney Docket No. 1761-0013  
)  
)  
) Examiner: To be assigned  
)  
)  
) Group Art Unit: 1614  
)  
)

1614  
#411  
OCT 17 2002  
RECEIVED  
TECH CENTER 1600/2900

I hereby certify that this correspondence is being  
deposited with the United States Postal Service  
with sufficient postage as first class mail in an  
envelope addressed to: Commissioner of Patents,  
Washington, D.C. 20231 on October 8, 2002  
(Date of Deposit)

Paul J. Maginot

Name of person mailing Document or Fee

Signature of person mailing Document or Fee

October 8, 2002

Date of Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, Applicants hereby disclose the following references, copies  
of which are enclosed, regarding the above-identified patent application.

<u>U.S. Patent Number</u>	<u>Inventor(s)</u>	<u>Issue Date</u>
5,824,702	Wei	10/20/1998
6,060,070	Gorbach	05/09/2000

<u>Foreign Patent Number</u>	<u>Country</u>	<u>Issue Date</u>
JP 7157494 – abstract only	Japan	20 June 1995
2,782,919	France	04 September 1998

Other Publications

1. Kawashima, K. et al., "Effect of KCA-098 on the Function of Osteoblast-Like Cells and the Formation of TRAP-Positive Multinucleated Cells in a Mouse Bone Marrow Cell Population", *Biochemical Pharmacology*, Vol. 51, pp. 133-139, 1996.
2. Shao, Z. et al., "Genistein Inhibits Both Constitutive and EGF-Stimulated Invasion in ER-Negative Human Breast Carcinoma Cell Lines", *Anticancer Research*, Vol. 18, pp. 1435-1440, 1998.
3. Maroulis, G., "Alternatives to Estrogen Replacement Therapy", *Annals New York Academy of Sciences*, pp. 413-415.

The foregoing references are also listed on the PTO-1449 Form, which is submitted contemporaneously herewith.


In accordance with 37 C.F.R. § 1.98(a)(3), Applicant's undersigned representative submits the following concise explanation of the relevance of the non-English language document cited above and on the accompanying form PTO-1449:

The document FR 2 782 919 discloses a cosmetic composition, characterized in that it comprises an association of (a) at least one retinoid selected from the group consisting of retinol, esters thereof and retinaldehydes, with (b) at least one plant hormone selected from the group consisting of phyto-sterols, ethoxylated derivatives thereof, pentacyclic triterpenes, isoflavones, isoflavone glucosides, coumestanes and saponinsides, and (c) at least one cosmetically acceptable excipient. This composition particularly reduces in a visible way the effects associated with the aging of the skin and the exoskeleton.

It is believed that no fees are due for the consideration of this Supplemental Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 13-0014, but not to include any payment of issue fees.

Respectfully submitted,

MAGINOT, MOORE & BOWMAN



Paul J. Maginot  
Attorney for Applicants  
Registration No. 34,984

October 8, 2002

Maginot, Moore & Bowman  
Bank One Center Tower  
111 Monument Circle, Suite 3000  
Indianapolis, Indiana 46204-5115  
(317) 638-2922 phone  
(317) 638-2139 facsimile